PharmaResearch is a South Korean pharmaceutical and medical device manufacturer established in 2001. The company develops, manufactures, and distributes products based on Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) technologies derived from salmon DNA. Its business segments include pharmaceuticals, medical devices, and cosmetics. Key products include the skin booster Rejuran, the joint injection Conjuvan, the ophthalmic solution Rejuvenex, and the botulinum toxin Lientox. The company also imports and distributes imported pharmaceuticals. PharmaResearch serves domestic hospitals and clinics as well as international markets in Asia, Europe, and North America. Its subsidiary, PharmaResearch Bio, specializes in botulinum toxin production and export. The company operates GMP-certified manufacturing facilities in Gangneung, South Korea.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage pharmaresearch.com
Sector Healthcare IR page pharmaresearch.com
Tags
regenerative medicine, skin boosters, botulinum toxin, ophthalmic solutions, joint injections, cosmetics, pdrn, pn, anti-aging, dermatology, Rejuran, Conjuvan, Rejuvenex, Lientox, Placentex, Zadakxin, Clavil, Rejuviel, Rejuran Cosmetic, PharmaResearch Bio, PharmaResearch Medicaire
Press page —

Metrics

Valuation  
Market cap ₩ 6.263T
Market cap (USD) $ 4.61B
P/E 14.49
PEG 0.24
P/BV 8.31
P/S 10.38
P/OCF 36.23
P/FCF 45.42
Dividend yield —
Turnover / mcap —
Returns  
ROE 26.9%
ROI 24.0%
ROIC 24.2%
Profit margin 30.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 59.7%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 53.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 536.289B 350.115B 261.011B 194.759B 154.083B 108.746B 83.872B 64.281B 54.47B 45.953B 37.455B 24.765B 17.771B
Net profit 165.121B 92.043B 76.551B 40.577B 46.689B 32.774B 16.667B 14.408B 12.956B 13.909B 12.878B 8.838B 5.662B
Free cash flow 153.435B 101.707B 52.883B 42.19B 44.652B -2.393B 9.687B -23.394B 1.803B 6.783B 15.673B -3.864B 1.708B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 536K — — — — — — — — — — — —
P/FCF 40.82 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 10.8B 15B 15.9B 20.2B 22.8B 27.7B 32.3B 31.4B 38.5B 44.5B
↳ YoY growth +84.3% +38.9% +5.9% +27.3% +13.0% +21.5% +16.4% -2.8% +22.5% +15.7%
↳ 5y CAGR +34.2% +26.4% +31.3% +20.8% +16.6% +14.6% +13.7% +14.3%
Other receivables (KRW) — 3.05B — — — — — 4.6B 18.1B 12.8B
Borrowings, current (KRW) 0.00 0.00 — — 15B 15.8B 15.6B 400M 9.36B 7.97B
Borrowings, non-current (KRW) 0.00 0.00 1.83B 1.22B 773M 21.3B 22.3B 193M 1.22B 434M
Bonds payable (KRW) — 0.00 — — — 20.6B 22.1B 0.00 9.11B 7.97B
Lease liabilities (KRW) — — — 358M 1.12B 2.63B 2.46B 958M 3.54B 2.05B
Cash and deposits (KRW) 17.6B 17B 21.1B 19.7B 26.7B 41.7B 72.9B 67.2B 165B 176B
Intangible assets (KRW) 4.21B 3.32B 45.7B 43.5B 39.3B 42.8B 37.8B 32B 33.4B 31.5B
Net debt (borrowings + leases - cash) (KRW) -17.6B -17B -19.3B -18.2B -9.82B -1.96B -32.6B -65.7B -151B -165B
Cash flow detail
Operating cash flow (KRW) 8.16B 8.56B 5.2B 19.3B 32.4B 65.3B 59.4B 64.9B 138B 183B
Purchases of property, plant and equipment (KRW) -1.38B -6.75B -28.6B -9.59B -34.8B -20.6B -17.2B -12.1B -36.4B -29.7B
Purchases of intangible assets (KRW) -580M -121M -838M -198M -598M -3.14B -544M -1.13B -2.31B -6.05B
Dividends paid (cash effect) (KRW) -1.89B -2.82B -2.8B -2.97B -2.96B -5.03B -6.32B -7.53B -10.1B -11.7B
Share buybacks (cash effect) (KRW) -2.68B -2.3B — -4.99B — — — — — —
Interest paid (cash effect) (KRW) 0.00 -7.78M -75.9M -184M -117M -196M -159M -494M -429M -2.18B
Income taxes paid (cash effect) (KRW) -4.01B -3.43B -4.55B -2.49B -5.86B -10.1B -13.8B -17B -19.8B -39.6B
Free cash flow (OCF - PPE - intangibles) (KRW) 6.2B 1.68B -24.2B 9.49B -2.99B 41.5B 41.6B 51.7B 99.4B 147B
Income detail
Total comprehensive income (KRW) 14B 11.9B 12B 15.3B 32.1B 46.2B 39.4B 78.6B 90.8B 168B
Comprehensive income to owners (KRW) 14.1B 12.4B 15B 17.1B 32.4B 46.1B 36.6B 77.7B 94B 165B
Provision for credit losses (KRW) 65M — — — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 0.8% — — — — — — — — —
Reported Apr 2, 2018 Aug 14, 2018 Mar 29, 2019 Mar 27, 2020 Mar 18, 2021 Mar 15, 2024 Mar 15, 2024 Mar 19, 2026 May 21, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

주식등의대량보유상황보고서(일반) Bull 0 Bear 0 Routine

Prompts

PharmaResearch (ticker 214450), listed in South Korea.

ETFs Holding PharmaResearch

ETF Weight in ETF Shares Market value As of
AVEE 0.13% 904 $ 172.855K Nov 16, 2026
AVXC 0.05% 988 $ 188.917K Nov 16, 2026
DFSE 0.03% 996 $ 185.283K Nov 12, 2026
DEHP 0.03% 554 $ 103.059K Nov 12, 2026
DEXC 0.02% 329 $ 61.203K Nov 12, 2026
AVEM 0.02% 22,522 $ 4.306M Nov 16, 2026
DFEM 0.02% 9,499 $ 1.767M Nov 12, 2026
DFAE 0.01% 5,622 $ 1.046M Nov 12, 2026
DFAX 0.01% 6,461 $ 1.202M Nov 12, 2026
AVSE 0.00% 43 $ 8,222.08 Nov 16, 2026